CDX2, COX2 and MUC2 expressions in Barrett's esophagus: Can they be useful in determination of the dysplasia?;Barrett özofagusunda CDX2, COX2 ve MUC2 ekspresyonu: Displazinin belirlenmesinde yardımcı olabilir mi?

Turk Patoloji Dergisi/Turkish Journal of Pathology

Volumn 28, Issue 3, 2012, Pages 251-258

  Türkmen, Ilknur Çetinaslan ^a   Başsüllü, Nuray ^a   Uraz, Süleyman ^b   Yerdel, Mehmet Ali ^c   Memişoǧlu, Reşat ^b   Doǧusoy, Gülen Bülbül ^b  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

^b FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

^c Istanbul Surgery Hospital   (Turkey)

Author keywords

Barrett esophagus; Biopsy; CDX2 protein; COX2 protein; Immunohistochemistry; Immunology; MUC2 protein; Pathology

Indexed keywords

CYCLOOXYGENASE 2; MUCIN 2; TRANSCRIPTION FACTOR CDX2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DYSPLASIA; GOBLET CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SQUAMOUS EPITHELIUM;

EID: 84867082319     PISSN: 10185615     EISSN: 13095730     Source Type: Journal    
DOI: 10.5146/tjpath.2012.01132     Document Type: Article

References (22)

1. Fenoglio C: Gastrointestinal Pathology, an atlas and text. 3rd ed., Philadelphia, Lippincott Wilkins, 2008, 62-68
2. Odze RD: Update on the diagnosis and treatment of Barrett esophagus and related neoplastic precursor lesions. Arch Pathol Lab Med 2008, 132:1577-1585
3. Riddell RH, Odze RD: Definition of Barrett's esophagus: time for a rethink-Is intestinal metaplasia dead? Am J Gastroenterol 2009, 104:2588-2594
4. Souza RF, Krishnan K, Spechler SJ: Acid, Bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008, 295:G211-G218
5. Phillips RW, Frierson HF Jr, Moskaluk CA: Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003, 27:1442-1447
6. Groisman GM, Amar M, Meir A: Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004,17:1282-1288
7. Colleypriest BJ, Palmer RM, Ward SG, Tosh D: Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends in Molecular Medicine 2009,15:313-322
8. Burjonrappa SC, Reddimasu S, Nawaz Z Gao X, Sharma P, Loggie B: Mucin expression profile in Barrett's, dysplasia, adenocarcinoma sequence in the esophagus. Indian J Cancer 2007, 44:1-5
9. Chinyama CN, Marshall RE, Owen WJ, Mason RC, Kothari D, Wilkinson ML, Sanderson JD: Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999, 35:517-524
10. Van De Bovenkamp JH, Korteland-Van Male AM, Warson C, Büller HA, Einerhand AW, Ectors NL, Dekker J: Gastric-type mucin and TFF-peptide expression in Barrett's oesophagus is disturbed during increased expression of MUC2. Histopathology 2003, 42:555-565
11. Hu Y, Jones C, Gellersen O, Williams VA, Watson TJ, Peters JH: Pathogenesis of Barrett esophagus deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells. Arch of Surg 2007, 142:540-545
12. Steininger H, Pfofe DA, Müller H, Haag-Sunjic G, Fratianu V: Expression of CDX2 and MUC2 in Barrett's mucosa. Pathol Res Pract 2005, 201:573-577
13. Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallböhmer D, Schäfer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Hölscher AH, Meltzer SJ, Schneider PM: The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005, 14:2113-2117
14. Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Lambeth D, Cao W: NADPH oxidase NOX5-S mediates acidinduced cyclooxygenase-2 expression via activation of NF-kappa B in Barrett's esophageal adenocarcinoma cells. Biol Chem 2007, 282:16244-16255
15. Song S, Guha S, Liu K, Buttar NS, Bresalier RS: COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007, 56:1512-1521
16. Hahn HP, Blount PL, Ayub K, Das KM, Souza R, Spechler S, Odze RD: Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am J Surg Pathol 2009, 33:1006-1015
17. Villanacci V, Rossi E, Zambelli C, Galletti A, Cestari R, Missale G, Casa DD, Bassotti G: COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig Liver Dis 2007, 39:305-311
18. Chaves P, Cruz C, Dias Pereira A, Suspiro A, de Almeida JC, Leitão CN, Soares J: Gastric and intestinal differentiation in Barrett's metaplasia and associated adenocarcinoma. Dis Esophagus 2005, 18:383-387
19. Weimann A, Zimmermann M, Gross M, Slevogt H, Rieger A, Morawietz L: CDX2 an LI-Cadherin expression in esophageal mucosa: Use of both markers can facilitate the histologic diagnosis of Barrett's Esophagus and carcinoma. Int J Surg Pathol 2010, 18:330-337
20. Glickman JN, Blount PL, Sanchez CA, Cowan DS, Wongsurawat VJ, Reid BJ, Odze RD: Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol 2006, 37:1304-1315
21. Möbius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, Gais P, Jütting U, Siewert JR: COX2 expression, angiogenesis, proliferation and survival in Barrett's cancer. Eur J Surg Oncol 2005, 31:755-759
22. Majka J, Rembiasz K, Migaczewski M, Budzynski A, Ptak-Belowska A, Pabianczyk R, Urbanczyk K, Zub-Pokrowiecka A, Matlok M, Brzozowski T: Cyclooxygenase-2 (COX2) is the key event in pathophysiology of Barrett's esophagus, lesson from experimental animal model and human subjects. J Physiol Pharmacol 2010, 61:409-418